Last reviewed · How we verify
BOTOX®/VISTABEL®
BOTOX is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
BOTOX is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Moderate to severe glabellar lines (frown lines), Moderate to severe lateral canthal lines (crow's feet), Moderate to severe forehead lines.
At a glance
| Generic name | BOTOX®/VISTABEL® |
|---|---|
| Sponsor | AbbVie |
| Drug class | Botulinum toxin |
| Target | SNARE complex (synaptosome-associated protein) |
| Modality | Small molecule |
| Therapeutic area | Dermatology, Neurology, Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle release, preventing muscle contraction. This results in temporary paralysis of injected muscles, lasting 3-4 months. The effect is reversible as the body gradually regenerates the damaged nerve terminals.
Approved indications
- Moderate to severe glabellar lines (frown lines)
- Moderate to severe lateral canthal lines (crow's feet)
- Moderate to severe forehead lines
- Chronic migraine
- Cervical dystonia
- Blepharospasm
- Strabismus
- Hyperhidrosis (excessive sweating)
Common side effects
- Headache
- Injection site pain
- Facial paresis
- Eyelid ptosis
- Brow ptosis
- Nausea
Key clinical trials
- A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections (PHASE4)
- Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides (PHASE4)
- Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®
- Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines (PHASE4)
- Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds (PHASE4)
- Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines (PHASE4)
- NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |